Patent US5385935A successfully refreshed from Google Patents.
US5385935A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for the inhibition of restenosis associated with coronary intervention
Assignee: Kissei Pharmaceutical Co Ltd
•
Filing: 1993-09-07
•
Granted: 1995-01-31
•
Expires: 2013-09-07
Abstract
Abstract This invention provides a method for treating patients to inhibit restenosis associated with coronary intervention. A 600 mg dosage of Tranilast for a treatment period of three consecutive months after coronary intervention lowers the incidence of restenosis, and reduces the degree of stenosis in patients.
Inventors
- 👤 Hideo Tamai
- 👤 Kinzo Ueda
- 👤 Yung-sheng Hsu
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 15:03
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61P; A61P43/00; A61P9/00; A61P9/10
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
49 words
A method for the inhibition restenosis associated with coronary intervention in a human patient, which comprises administering to the patient 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid or a pharmaceutically acceptable salt thereof in a daily dose of about 300-1000 mg for a treatment period of at least three consecutive months after coronary intervention.
Claim 2
Independent Claim
49 words
A method for the inhibition restenosis associated with coronary intervention in a human patient, which comprises administering to the patient 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid or a pharmaceutically acceptable salt thereof in a daily dose of about 300-1000 mg for a treatment period of at least three consecutive months after coronary intervention.
Claim 3
Dependent Claim
24 words
A method in accordance with claim 1 wherein the dosage is between about 300-600 mg of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid or a pharmaceutically acceptable salt thereof.
Claim 4
Dependent Claim
20 words
A method in accordance with claim 1 wherein the treatment period is between about 3-6 consecutive months after coronary intervention.
Claim 5
Dependent Claim
13 words
A method in accordance with claim 1 wherein the dosage is administered orally.
Claim 6
Dependent Claim
13 words
A method in accordance with claim 1 wherein the dosage is administered parenterally.
Claim 7
Dependent Claim
16 words
A method in accordance with claim 1 wherein the coronary intervention is Percutaneous Transluminal Coronary Angioplasty.
Claim 8
Dependent Claim
15 words
A method in accordance with claim 1 wherein the coronary intervention is Direction Coronary Atherectomy.
Claim 9
Dependent Claim
13 words
A method in accordance with claim 1 wherein the coronary intervention is Stent.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-01-30 | 1998-08-01 | 1999-01-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-01-30 | 2002-08-01 | 2003-01-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-01-30 | 2006-08-01 | 2007-01-31 | $7700.00 | Window Closed / Lapsed |